2025 Highlights: A year of global growth and impact

As we head into the final days of 2025, I’m proud of what we’ve achieved together and energized by what comes next. Before many of us take a well-deserved break, I want to take a moment to reflect on a year defined by progress, focus, and meaningful impact. 

Looking back, 2025 has strengthened our position in the global clinical research technology and clinical trials market in meaningful ways. We welcomed almost 100 new clients and further expanded a global presence. We also broadened our footprint—most notably with the establishment of a local Australian entity and team to better serve our local customers in Australia & New Zealand, and dedicated support with a new team member in Brazil to strengthen our presence in the Latin and South America.  

This year also brought several strategic milestones. We were proud to be recognized as a Major Contender in the Everest Group Life Sciences eCOA PEAK Matrix® 2025, reflecting Viedoc’s intuitive design, responsive customer support, and strong global reach. We extended our Free License Initiative to continue supporting important global clinical research and completed a major leadership transition—one I’m honored to carry forward with a deep commitment to stability, innovation, and customer value. In addition, we launched the Viedoc Verified partner program, giving our customers added transparency and confidence in the ecosystem surrounding our technology. 

Partnerships continued to play a central role in our strategy. Our collaboration with A2 Healthcare is pushing the boundaries of RBM innovation in clinical study management, while our joint digital RWE pilot with LINK Medical demonstrates the growing potential of decentralized and real-world evidence–driven clinical research. Looking ahead, our CRO partnership program will be a core strategic focus for 2026 as we continue building a powerful global network that enables our CRO partners to grow and win with our support. 

On the product side, we’ve continued to invest heavily in scalability, security, and long-term sustainability. I’m especially excited about our upcoming releases, which introduce meaningful new capabilities inspired directly by customer feedback. These enhancements will elevate how our customers design, manage, and scale their studies, ultimately accelerating the path from research to bringing new therapies to patients faster. I am also happy to report that we managed to sustain the highest cyber-security grade when it comes to our external security footprint, measured by the Fortifydata risk management tool, compared to our industry and competitors. 

In short, 2025 has been a year of momentum, learning, and important steps forward. Thank you to everyone—our teams, customers, and partners—who have contributed to this journey. I’m excited for what 2026 holds and look forward to building on this progress together.

Warm wishes,  
Philip McCrea
CEO